Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Lyell Immunopharma, Inc. (LYEL)
|
Add to portfolio |
|
|
|
| Price: |
$7.05
| | Metrics |
| OS: |
251.0
|
M
| |
|
|
| Market cap: |
$1.77
|
B
| |
|
|
|
Net cash:
|
$633
|
M
| |
$2.52
|
per share
|
|
EV:
|
$1.14
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($210)
|
M
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 84.7 | 10.7 | 7.8 | 0.7 |
| Revenue growth | 695.1% | 37.3% | 1080.5% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 84.7 | 10.7 | 7.8 | 0.7 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | | 138.7 | 182.2 | 63.6 |
| General and administrative | 117.3 | 89.1 | 46.9 | 39.2 |
| EBIT | -187.1 | -214.8 | -211.9 | -102.1 |
| EBIT margin | -220.9% | -2016.7% | -2732.6% | -15538.7% |
| Pre-tax income | 0.0 | -250.2 | -204.5 | -129.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.0% |
| Net income | 0.0 | -250.2 | -208.1 | -130.5 |
| Net margin | 0.0% | -2349.5% | -2682.5% | -19866.2% |
| |
| Diluted EPS | | ($1.84) | ($15.69) | ($24.04) |
| Shares outstanding (diluted) | | 135.9 | 13.3 | 5.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|